ERCC1BRCA1RRM1表达在晚期非小细胞肺癌个体化治疗中前瞻性研究.docVIP

ERCC1BRCA1RRM1表达在晚期非小细胞肺癌个体化治疗中前瞻性研究 　　[摘要]目的 探讨切除修复交叉互补基因1（ERCC1）、乳腺癌易感基因1（BRCA1）、核糖核苷酸还原酶M1亚基（RRM1）表达在晚期非小细胞肺癌（NSCLC）个体化治疗中的应用价值。方法 选择2015年6月～2016年8月在我院就诊的晚期NSCLC患者50例作为研究对象，采取奇偶数分组模式进行分组，每组25例，其中实验组对ERCC1、BRCA1、RRM1水平进行检测，依据检测结果对化疗方案进行选择，常规组直接给予吉西他滨联合顺铂治疗。比较两组的治疗效果。结果 实验组的化疗总有效率为72.00%，明显高于常规组的56.00%，差异有统计学意义（P0.05）；实验组发生12例血液系统反应，7例消化道反应，3例其他；常规组发生13例血液系统反应，7例消化道反应，3例其他，两组的不良反应发生率比较，差异无统计学意义（P0.05）。结论 对ERCC1、BRCA1、RRM1水平进行检测，并依据检测水平指导晚期NSCLC患者的治疗，便于提高临床效果。 　　[关键词]晚期非小细胞肺癌；个体化治疗；ERCC1；BRCA1；RRM1 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721（2017）11（b）-0056-03 　　[Abstract]Objective To investigate the application value of excision repair cross-complementing gene 1 （ERCC1），breast cancer susceptibility gene 1 （BRCA1），and ribonucleotide reductase M1 subunit （RRM1） expression in the individualized treatment of advanced non-small cell lung cancer （NSCLC）.Methods From June 2015 to August 2016，50 patients with advanced NSCLC visited our hospital were recruited as research subjects.Using an odd/even number grouping model，they were grouped and there were 25 cases in each group.In the experimental group，the level of ERCC1，BRCA1，and RRM1 were tested，and the corresponding chemotherapy regimen was selected based on the outcomes.In the conventional group，Gemcitabine combined with Cisplatin was provided.The therapeutic effect was compared between the two groups.Results The total effective rate of chemotherapy in the experimental group was 72.00%，which was obviously higher than that of the conventional group，and there was a statistical difference （P0.05）.In the experimental group，there were blood system reaction in 12 cases，digestive tract reaction in 7 cases，and other in 3 ones.In the conventional group，there were blood system reaction in 13 cases，digestive tract reaction in 7 cases，and other in 3 ones.There was no statistical difference of the incidence of adverse reaction between the two groups （P0.05）.Conclusion Test for the level of ERCC1，BRCA1，and RRM1 and guidance of cli